Effect of central precocious puberty and gonadotropin-releasing hormone analogue treatment on peak bone mass and final height in females.

What Was Tested

This clinical trial looks at Gonadotropin-Releasing Hormone and Buserelin.

To evaluate the effect of central precocious puberty (CPP) and its treatment with gonadotropin-releasing hormone (GnRH) analogues on final height and peak bone mass (PBM), the researchers measured lumbar bone mineral density (BMD) in 23 girls at final height.

Why It Was Studied

Patients were distributed in two groups.

Who Took Part

The abstract describes 23 girls taking part.

PubMed indexes the participants as young children, children and teenagers, women only.

Group 2: 9 patients (mean age 6.5 years, range 4.8-7.7 years) with a slowly progressing variant of CPP were followed without treatment; final height was reached at the mean age 13.6 years (range 12.5-14.8 years).

Lumbar BMD (L2-L4 by dual energy X-ray absorptiometry) was measured in all patients at final height.

What Was Measured

PubMed files the paper under topics including Body Height, Bone Density, Buserelin, Gonadotropin-Releasing Hormone, Puberty, Precocious, Regression Analysis and Triptorelin Pamoate.

What This Means in Plain Language

This is a clinical trial of Gonadotropin-Releasing Hormone and Buserelin in 23 girls.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

The abstract goes on to report its results in about 4 sentences; this page does not restate them, so read the paper for the findings and their limits.

The publication is from 1998 (European journal of pediatrics), a journal based in Germany.

More context: all human trials.